Berberine: A Promising Treatment for Type 2 Diabetes Mellitus and Its Associated Dementia – A Review
DOI:
https://doi.org/10.12775/QS.2024.24.55029Keywords
Alzheimer disease, Berberine, Vascular Dementia, Diabetes Mellitus type 2Abstract
Introduction and objective: Berberine (BBR) is an isoquinoline alkaloid extracted from various plants. It has been utilized for millennia in traditional Chinese and Ayurvedic medicine. A growing body of evidence supports the beneficial effects of BBR in the treatment of type 2 diabetes mellitus (T2DM) and in reducing the risk of developing related complications. The aim of this study is to review the existing knowledge on the efficacy and safety of BBR in the treatment of T2DM and associated dementia, based on the available scientific literature.
Material and Methods: A review of the literature available in the PubMed database was conducted using the following search terms: Berberine; Diabetes Mellitus Type 2; Vascular Dementia; Alzheimer Disease.
Current knowledge: The pharmacological treatments of both T2DM and AD have been associated with relatively low efficacy, a high financial burden, and numerous complications that significantly impact patients' daily lives. The exact mechanisms of action of berberine remain unclear.
Summary: BBR may be an attractive option for the treatment of T2DM and associated dementia, with therapeutic effects similar to oral hypoglycemic agents, promising neuroprotective properties, a reduced risk of adverse reactions and lower cost. Moreover, BBR improves cerebral blood flow and memory in the rat model of AD. Further scientific research is required to determine the long-term outcomes of this treatment.
References
Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, Ostolaza H, Martín C. Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci. 2020 Aug 30;21(17):6275. doi: 10.3390/ijms21176275. PMID: 32872570; PMCID: PMC7503727.
Virally M, Blicklé JF, Girard J, Halimi S, Simon D, Guillausseau PJ. Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives. Diabetes Metab. 2007 Sep;33(4):231-44. doi: 10.1016/j.diabet.2007.07.001. Epub 2007 Aug 20. PMID: 17703979.
Sartore G, Ragazzi E, Antonello G, Cosma C, Lapolla A. Effect of a New Formulation of Nutraceuticals as an Add-On to Metformin Monotherapy for Patients with Type 2 Diabetes and Suboptimal Glycemic Control: A Randomized Controlled Trial. Nutrients. 2021 Jul 11;13(7):2373. doi: 10.3390/nu13072373. PMID: 34371883; PMCID: PMC8308828.
Sapra A, Bhandari P. Diabetes. 2023 Jun 21. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 31855345.
Magliano DJ, Boyko EJ; IDF Diabetes Atlas 10th edition scientific committee. IDF DIABETES ATLAS [Internet]. 10th ed. Brussels: International Diabetes Federation; 2021. PMID: 35914061.
Panigrahi A, Mohanty S. Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial. BMC Endocr Disord. 2023 Sep 7;23(1):190. doi: 10.1186/s12902-023-01442-y. PMID: 37679692; PMCID: PMC10483788.
Cai Z, Wang C, Yang W. Role of berberine in Alzheimer's disease. Neuropsychiatr Dis Treat. 2016 Oct 3;12:2509-2520. doi: 10.2147/NDT.S114846. PMID: 27757035; PMCID: PMC5055107.
Liang Y, Xu X, Yin M, Zhang Y, Huang L, Chen R, Ni J. Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic literature review and a meta-analysis. Endocr J. 2019 Jan 28;66(1):51-63. doi: 10.1507/endocrj.EJ18-0109. Epub 2018 Nov 3. PMID: 30393248.
Tomic D, Shaw JE, Magliano DJ. The burden and risks of emerging complications of diabetes mellitus. Nat Rev Endocrinol. 2022 Sep;18(9):525-539. doi: 10.1038/s41574-022-00690-7. Epub 2022 Jun 6. PMID: 35668219; PMCID: PMC9169030.
Cook MN, Girman CJ, Stein PP, Alexander CM. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. Diabet Med. 2007 Apr;24(4):350-8. doi: 10.1111/j.1464-5491.2007.02078.x. Epub 2007 Feb 28. PMID: 17335466.
Pang B, Zhao LH, Zhou Q, Zhao TY, Wang H, Gu CJ, Tong XL. Application of berberine on treating type 2 diabetes mellitus. Int J Endocrinol. 2015;2015:905749. doi: 10.1155/2015/905749. Epub 2015 Mar 11. PMID: 25861268; PMCID: PMC4377488.
.Zhang JH, Zhang JF, Song J, Bai Y, Deng L, Feng CP, Xu XY, Guo HX, Wang Y, Gao X, Gu Y, Jin C, Zheng JF, Zhen Z, Su H. Effects of Berberine on Diabetes and Cognitive Impairment in an Animal Model: The Mechanisms of Action. Am J Chin Med. 2021;49(6):1399-1415. doi: 10.1142/S0192415X21500658. Epub 2021 Jun 16. PMID: 34137676.
Cao F, Yang F, Li J, Guo W, Zhang C, Gao F, Sun X, Zhou Y, Zhang W. The relationship between diabetes and the dementia risk: a meta-analysis. Diabetol Metab Syndr. 2024 May 14;16(1):101. doi: 10.1186/s13098-024-01346-4. PMID: 38745237; PMCID: PMC11092065.
Liu X, Mo Y, Gong J, Li Z, Peng H, Chen J, Wang Q, Ke Z, Xie J. Puerarin ameliorates cognitive deficits in streptozotocin-induced diabetic rats. Metab Brain Dis. 2016 Apr;31(2):417-23. doi: 10.1007/s11011-015-9779-5. Epub 2015 Dec 19. PMID: 26686502.
Biessels GJ. Brain MRI correlates of cognitive dysfunction in type 2 diabetes: the needle recovered from the haystack? Diabetes Care. 2013 Dec;36(12):3855-6. doi: 10.2337/dc13-1501. PMID: 24265363; PMCID: PMC3836090.
Stanley M, Macauley SL, Holtzman DM. Changes in insulin and insulin signaling in Alzheimer's disease: cause or consequence? J Exp Med. 2016 Jul 25;213(8):1375-85. doi: 10.1084/jem.20160493. Epub 2016 Jul 18. PMID: 27432942; PMCID: PMC4986537.
Shinjyo N, Parkinson J, Bell J, Katsuno T, Bligh A. Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review. J Integr Med. 2020 Mar;18(2):125-151. doi: 10.1016/j.joim.2020.01.004. Epub 2020 Jan 16. PMID: 32005442.
Zhu F, Qian C. Berberine chloride can ameliorate the spatial memory impairment and increase the expression of interleukin-1beta and inducible nitric oxide synthase in the rat model of Alzheimer's disease. BMC Neurosci. 2006 Dec 1;7:78. doi: 10.1186/1471-2202-7-78. PMID: 17137520; PMCID: PMC1693919.
Yin S, Bai W, Li P, Jian X, Shan T, Tang Z, Jing X, Ping S, Li Q, Miao Z, Wang S, Ou W, Fei J, Guo T. Berberine suppresses the ectopic expression of miR-133a in endothelial cells to improve vascular dementia in diabetic rats. Clin Exp Hypertens. 2019;41(8):708-716. doi: 10.1080/10641963.2018.1545846. Epub 2018 Nov 26. PMID: 30472896.
Wei Z, Koya J, Reznik SE. Insulin Resistance Exacerbates Alzheimer Disease via Multiple Mechanisms. Front Neurosci. 2021 Jul 19;15:687157. doi: 10.3389/fnins.2021.687157. PMID: 34349617; PMCID: PMC8326507.
Fang Z, Tang Y, Ying J, Tang C, Wang Q. Traditional Chinese medicine for anti-Alzheimer's disease: berberine and evodiamine from Evodia rutaecarpa. Chin Med. 2020 Aug 5;15:82. doi: 10.1186/s13020-020-00359-1. PMID: 32774447; PMCID: PMC7409421.
Jiang W, Li S, Li X. Therapeutic potential of berberine against neurodegenerative diseases. Sci China Life Sci. 2015 Jun;58(6):564-9. doi: 10.1007/s11427-015-4829-0. Epub 2015 Mar 6. PMID: 25749423; PMCID: PMC5823536.
Lazarević-Pašti Т. Side Effects of Alzheimer's Disease Treatment. Curr Med Chem. 2023;30(24):2705-2709. doi: 10.2174/0929867330666230112160522. PMID: 36635902.
Tang BC, Wang YT, Ren J. Basic information about memantine and its treatment of Alzheimer's disease and other clinical applications. Ibrain. 2023 Jun 6;9(3):340-348. doi: 10.1002/ibra.12098. PMID: 37786758; PMCID: PMC10527776.
Guo J, Chen H, Zhang X, Lou W, Zhang P, Qiu Y, Zhang C, Wang Y, Liu WJ. The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Oxid Med Cell Longev. 2021 Dec 15;2021:2074610. doi: 10.1155/2021/2074610. PMID: 34956436; PMCID: PMC8696197.
Lan J, Zhao Y, Dong F, Yan Z, Zheng W, Fan J, Sun G. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015 Feb 23;161:69-81. doi: 10.1016/j.jep.2014.09.049. Epub 2014 Dec 10. PMID: 25498346.
Ilyas Z, Perna S, Al-Thawadi S, Alalwan TA, Riva A, Petrangolini G, Gasparri C, Infantino V, Peroni G, Rondanelli M. The effect of Berberine on weight loss in order to prevent obesity: A systematic review. Biomed Pharmacother. 2020 Jul;127:110137. doi: 10.1016/j.biopha.2020.110137. Epub 2020 Apr 27. PMID: 32353823.
Zhang Y, Gu Y, Ren H, Wang S, Zhong H, Zhao X, Ma J, Gu X, Xue Y, Huang S, Yang J, Chen L, Chen G, Qu S, Liang J, Qin L, Huang Q, Peng Y, Li Q, Wang X, Kong P, Hou G, Gao M, Shi Z, Li X, Qiu Y, Zou Y, Yang H, Wang J, Xu G, Lai S, Li J, Ning G, Wang W. Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). Nat Commun. 2020 Oct 6;11(1):5015. doi: 10.1038/s41467-020-18414-8. PMID: 33024120; PMCID: PMC7538905.
Darakjian L, Deodhar M, Turgeon J, Michaud V. Chronic Inflammatory Status Observed in Patients with Type 2 Diabetes Induces Modulation of Cytochrome P450 Expression and Activity. Int J Mol Sci. 2021 May 7;22(9):4967. doi: 10.3390/ijms22094967. PMID: 34067027; PMCID: PMC8124164.
Li ZY, Liu B, Zhuang XJ, Shen YD, Tian HR, Ji Y, Li LX, Liu F. [Effects of berberine on the serum cystatin C levels and urine albumin/creatine ratio in patients with type 2 diabetes mellitus]. Zhonghua Yi Xue Za Zhi. 2018 Dec 11;98(46):3756-3761. Chinese. doi: 10.3760/cma.j.issn.0376-2491.2018.46.007. PMID: 30541217.
Rodríguez-Rivera NS, Barrera-Oviedo D. Exploring the Pathophysiology of ATP-Dependent Potassium Channels in Insulin Resistance. Int J Mol Sci. 2024 Apr 6;25(7):4079. doi: 10.3390/ijms25074079. PMID: 38612888; PMCID: PMC11012456.
Zhao MM, Lu J, Li S, Wang H, Cao X, Li Q, Shi TT, Matsunaga K, Chen C, Huang H, Izumi T, Yang JK. Berberine is an insulin secretagogue targeting the KCNH6 potassium channel. Nat Commun. 2021 Sep 23;12(1):5616. doi: 10.1038/s41467-021-25952-2. Erratum in: Nat Commun. 2021 Oct 29;12(1):6342. doi: 10.1038/s41467-021-26635-8. PMID: 34556670; PMCID: PMC8460738.
Coppinger C, Pomales B, Movahed MR, Marefat M, Hashemzadeh M. Berberine: A Multi-Target Natural PCSK9 Inhibitor with the Potential to Treat Diabetes, Alzheimer's, Cancer and Cardiovascular Disease. Curr Rev Clin Exp Pharmacol. 2024;19(4):312-326. doi: 10.2174/0127724328250471231222094648. PMID: 38361373.
Su J, Luo Y, Hu S, Tang L, Ouyang S. Advances in Research on Type 2 Diabetes Mellitus Targets and Therapeutic Agents. Int J Mol Sci. 2023 Aug 29;24(17):13381. doi: 10.3390/ijms241713381. PMID: 37686185; PMCID: PMC10487533.
Liu JY, Dai Y, He YX, Lin L. Effect of berberine on cognitive function and β-amyloid precursor protein in Alzheimer's disease models: a systematic review and meta-analysis. Front Pharmacol. 2024 Jan 16;14:1301102. doi: 10.3389/fphar.2023.1301102. PMID: 38293672; PMCID: PMC10824956.
Zhao X, Ge P, Lei S, Guo S, Zhou P, Zhao L, Qi Y, Wei X, Wu W, Wang N, Guo R, Yang N, Xiao Q, Zhang Q, Zhu H. An Exosome-Based Therapeutic Strategy Targeting Neuroinflammation in Alzheimer's Disease with Berberine and Palmatine. Drug Des Devel Ther. 2023 Aug 17;17:2401-2420. doi: 10.2147/DDDT.S417465. PMID: 37609432; PMCID: PMC10441573.
Moghaddam HK, Baluchnejadmojarad T, Roghani M, Khaksari M, Norouzi P, Ahooie M, Mahboobi F. Berberine ameliorate oxidative stress and astrogliosis in the hippocampus of STZ-induced diabetic rats. Mol Neurobiol. 2014 Apr;49(2):820-6. doi: 10.1007/s12035-013-8559-7. Epub 2013 Oct 10. PMID: 24113841.
Brabazon F, Bermudez S, Shaughness M, Khayrullina G, Byrnes KR. The effects of insulin on the inflammatory activity of BV2 microglia. PLoS One. 2018 Aug 27;13(8):e0201878. doi: 10.1371/journal.pone.0201878. PMID: 30148836; PMCID: PMC6110462.
Wong LR, Tan EA, Lim MEJ, Shen W, Lian XL, Wang Y, Chen L, Ho PC. Functional effects of berberine in modulating mitochondrial dysfunction and inflammatory response in the respective amyloidogenic cells and activated microglial cells - In vitro models simulating Alzheimer's disease pathology. Life Sci. 2021 Oct 1;282:119824. doi: 10.1016/j.lfs.2021.119824. Epub 2021 Jul 12. PMID: 34265361.
Ismail H, Khalid D, Waseem D, Ijaz MU, Dilshad E, Haq IU, Bhatti MZ, Anwaar S, Ahmed M, Saleem S. Bioassays guided isolation of berberine from Berberis lycium and its neuroprotective role in aluminium chloride induced rat model of Alzheimer's disease combined with insilico molecular docking. PLoS One. 2023 Nov 1;18(11):e0286349. doi: 10.1371/journal.pone.0286349. PMID: 37910530; PMCID: PMC10619822.
Xuan WT, Wang H, Zhou P, Ye T, Gao HW, Ye S, Wang JH, Chen ML, Song H, Wang Y, Cai B. Berberine ameliorates rats model of combined Alzheimer's disease and type 2 diabetes mellitus via the suppression of endoplasmic reticulum stress. 3 Biotech. 2020 Aug;10(8):359. doi: 10.1007/s13205-020-02354-7. Epub 2020 Jul 29. PMID: 32832321; PMCID: PMC7391461.
Zhao Z, Yan J, Huang L, Yang X. Phytochemicals targeting Alzheimer's disease via the AMP-activated protein kinase pathway, effects, and mechanisms of action. Biomed Pharmacother. 2024 Apr;173:116373. doi: 10.1016/j.biopha.2024.116373. Epub 2024 Mar 4. PMID: 38442672.
Lin X, Zhang N. Berberine: Pathways to protect neurons. Phytother Res. 2018 Aug;32(8):1501-1510. doi: 10.1002/ptr.6107. Epub 2018 May 6. PMID: 29732634.
Behl T, Singh S, Sharma N, Zahoor I, Albarrati A, Albratty M, Meraya AM, Najmi A, Bungau S. Expatiating the Pharmacological and Nanotechnological Aspects of the Alkaloidal Drug Berberine: Current and Future Trends. Molecules. 2022 Jun 9;27(12):3705. doi: 10.3390/molecules27123705. PMID: 35744831; PMCID: PMC9229453.
Harrison SA, Gunn N, Neff GW, Kohli A, Liu L, Flyer A, Goldkind L, Di Bisceglie AM. A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. Nat Commun. 2021 Sep 17;12(1):5503. doi: 10.1038/s41467-021-25701-5. PMID: 34535644; PMCID: PMC8448729.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Izabela Staszczyk, Aleksandra Drabik, Dominika Szczotka, Dobromiła Osuch, Dominika Opala, Antonina Szemplińska, Klaudia Błachnio, Agnieszka Anderska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 83
Number of citations: 0
